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Abstract
Our retrospective analysis aimed to evaluate the clinical value of dose intensification schemes: WBRTand consecutive, delayed, or
simultaneous integrated boost (SIB) in brain metastasis (BM) management. Clinical data and overall survival (OS) of 468 patients
with BM from various primaries treated with 10 × 3 Gy WBRT (n = 195), WBRT+ 10 × 2 Gy boost (n = 125), or simultaneously
15 × 2.2 GyWBRT+0.7 Gy boost (n = 148) during a 6-year period were statistically analysed. Significant difference in OS could be
detected with additional boost to WBRT (3.3 versus 6.5 months) and this difference was confirmed for BMs of lung cancer and
melanoma and both for oligo- andmultiplex lesions. The OSwas prolonged for the RPA 2 and RPA3 categories, if patients received
escalated dose, 4.0 vs. 7.7 months; (p = 0.002) in class RPA2 and 2.6 vs. 4.2 months; (p < 0.0001) in the class RPA 3 respectively.
The significant difference in OS was also achieved with SIB. The shortened overall treatment time of SIB with lower WBRT
fraction dose exhibited survival benefit overWBRTalone, and could be applied for patients developing BMevenwith unfavourable
prognostic factors. These results warrant for further study of this approach with dose escalation using the lately available solutions
for hippocampus sparing and fractionated stereotactic irradiation. The simultaneous delivery of WBRTwith reduced fraction dose
and boost proved to be advantageous prolonging the OS with shortened treatment time and reduced probability for cognitive
decline development even for patients with poor performance status and progressing extracranial disease.
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Introduction
Alongside the improved efficacy of systemic treatments, the
incidence of brain metastases (BMs) steadily increases, rang-
ing 9–40% worldwide [1, 2]. The most common cancers that
metastasise to the brain include lung, breast, melanoma, renal
cell, and colorectal cancers [3]. The recent advances in che-
motherapy and the fast growing introduction of diverse mo-
lecular targeted approaches (including EGFR-, VEGFR-,
multikinase, B-RAF, MEK, ERK and immunoresponse
CTLA-4, PD-1, PD-L1 inhibitors) into the management of
these metastatic cancers lead to remarkable improvement in
the outcome of disseminated stage of these frequent tumours.
In the case of brain metastasis, though, the overall prognosis
remains poor: without any treatment 1–2 months, with pallia-
tive methods, 4–6 months of median survival can be expected
[4], depending (1) on the age and functional status of the
patient, (2) the extent of the underlying systemic disease,
and (3) the number of metastases [5]. Moreover, in 15% of
the cases, the primary tumour is still unknown at the time
when BMs are already diagnosed [4].
The common therapeutic mean is the palliative irradiation
with different possible methods to choose from. In case of
multiple BMs, the whole-brain irradiation (WBRT) is usually
performed with the dose of 10 × 3 Gy [6], whilst the cases
with less than three metastatic lesions (i.e. oligometastases)
were considered for surgery and/or radiosurgery with or with-
outWBRT [7, 8]. In the last decade, conclusions from relevant
clinical studies demonstrated the superiority of multimodal
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approaches over the single treatment method of neurosurgery,
stereotactic radiosurgery (SRS), and WBRT [9–11]. More re-
cently, in order to decrease the cognitive decline attributed to
the standard WBRT, the possibility of omitting the WBRT
came again into focus. The ASCO recommendation in 2014
did not include the routine addition of WBRT to SRS for
limited brain metastases, based on meta-analysis of published
clinical research [12, 13]. However, it could be substantially
criticised and several arguments (including survival benefit,
notable increase of intracerebral impairments, and more seri-
ous neurocognitive decline due to metastatic progression in
the brain) support the further application of combined ap-
proaches including the WBRT [14, 15].
At the same time, any mean to mitigate the treatment-
related brain toxicities, such as the use of radioprotective
agents, and/or hippocampus-sparing advanced radiation tech-
nique and/or alternative fractionation of WBRT, is highly re-
quired. The conformational fractionated external beam boost,
instead of SRS for BMs arising from lung cancer (as it has
been recently demonstrated in a multi-institutional study
[16]), results in a remarkable estimated 1-year local control
rate of >75%. Such dose escalation can be also carried out
with intensity-modulated radiotherapy (IMRT) or volumetric
modulated arc therapy (VMAT), using the simultaneous inte-
grated boost (SIB) technique [8, 17], or, if the above men-
tioned techniques are not available, with external beam radio-
therapy boost (RTB) [16].
Several technical and logistical advantages of SIB over other
modalities (such as radiosurgery) makes SIB a plausible choice.
SIB includes WBRTand boost on BM in the same session with
optimised dose distribution, requires a single simulation proto-
col, reducing the waiting and dose delivery time, therefore costs
and inconvenience, as well [18]. Using single fraction protocols,
the re-oxygenation and re-assortment benefits accompanying
fractionated modalities, cannot be exploited. The treatment of
more than 3 metastases with radiosurgery may require long or
multiple sessions, or may lead to the impossibility of radiosur-
gery, as well. The substantial time break between radiosurgery
and WBRT may enhance the probability of tumour cell repop-
ulation or subletal repair processes [19].
From 2005 on, the dose escalation with 3D conformal tech-
nique was introduced for patients presented with brain metas-
tasis at our Department, in the lack of SRS availability before
2016. The standard WBRT and the new approaches were per-
formed parallel; therefore we could evaluate the results of the
different radiation schemes in a single institutional retrospec-
tive analysis.
Materials and Methods
Between 2005 and 2013, at the Department of Oncotherapy,
altogether 468 patients with BMs (arising from various
primary malignancies) were subjected to palliative skull irra-
diation. The present study has been carried out in accordance
with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.
Informed consent was obtained from the patients at their first
clinical admission for the anonymised use of their patient data
for research purposes. For the present study, the ethical per-
mission (No. 886/2006) was issued by the Ethical Council of
the Faculty of Medicine, University of Szeged. The treatment
schemes were thoroughly discussed with every single patient,
independently from their actual performance status. The frac-
tionation was agreed by signed informed consent.
Unconscious patients or those with serious cognitive deficits,
lacking the legal capacity of informed consent made on their
own, and also patients with previous prophylactic WBRT,
were excluded from the enrolment. All patients included in
the present study were treated according to the actual protocol
for the histologically proven primary disease and had clinical,
radiological, pathological evidence of BM.
The total biological effective dose was calculated as equiv-
alent dose in 2 Gy fractions (EQD2:α/β value of 2 for normal
brain [Gy2] and that of 10 for tumour [Gy10]). The traditional
palliative approach of 10 × 3 GyWBRT (EQD2 37.5 Gy) was
applied for 195 cases (Group A); in 273 cases WBRT com-
bined with boost irradiation were performed. In addition to the
10 × 3 Gy /18x2Gy WBRT boost dose of 10 × 2 Gy (EQD2
57,5 Gy/ 56 Gy) to the surgical cavity (if the metastasis had
been removed), or to the metastatic lesions for patients in good
PS and/or better life expectancy were performed (Group B).
Later, simultaneous integrated boost irradiation (SIB: 15 × 2.2
WBRT+ 15 × 0.7 boost, (WBRT EQD2 33,4Gy, metastasis
EQD2 46.8 Gy) (Group C) had been given whenever it was
applicable with 3D conformal technique planned byXIO TPS.
Patients were immobilised with a 3-point thermoplastic
mask (ORFIT Industries, NL). Radiotherapy was planned ac-
cording to the ICRU 52 recommendation using subfields addi-
tionally to the opposed lateral fields to achieve the required
dose homogeneity (95–107%) for WBRT. Boost using 3
DCRT or IMRT at 10 × 2 Gy boost was given consecutively
or with 2–3 months delay, due to the treatment of either the
primary tumour or of the extracranial metastases. Later, we
have developed the technique of conformal simultaneous
boost, delivered whenever the metastases could be
encompassed in a boost volume less than 30% of the brain
(in majority of the cases less than 10%). Boost volume was
defined on the basis of planning CAT and MRI fusion.
During brain irradiation patients received 12 mg methyl-
prednisolone for prevention of brain oedema, with gradually
decreased dosing after radiotherapy. The dose of methyl-
prednisolone was adjusted according to the symptoms of intra-
cranial pressure elevation due to brain oedema. Retrospective
assessment of overall survival (OS) according to the recursive
partitioning analysis (RPA), Karnofsky performance score
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(KPS), number of metastases, metastasectomy, localisation and
histological features of primary tumour was carried out. The
data were evaluated by Kaplan-Meier statistical analysis with
IBM SPSS Statistics forWindows, Version 20.0 (Armonk, NY:
IBM Corp.) p value <0.05 was considered as statistically sig-
nificant. Multi-variance analysis of the prognostic factors was
performed using the Cox proportional hazard regressionmodel.
Results
Patient Characteristics
The mean age of the population at the time of BM detection
was 60.7 years; 53.3% of them was male and 46.7% female.
The KPS was in 56.2% of this population over 70%. The
primary neoplasm was that of the lung in 68.9% (16% of the
latter was small cell lung cancer without prior prophylactic
skull irradiation), of the breast in 7.9%, malignant melanoma
in 10.6%, of the kidney in 2.1%, of the gastrointestinal tract in
5.4%, or that of other organ in 4.9% of the assessed popula-
tion. 36% of patients with small cell lung cancer received
dose-escalated radiotherapy, the remaining cases were treated
with WBRT. At the time of the diagnosis of the cerebral me-
tastasis, the underlying process was controlled in 37.4%, ex-
tracranial progression in 35.8% and was unknown in 26.6% of
this population. 11.1% of all patients belonged to RPA 1,
45.1% to RPA 2, and 43.8% to RPA 3 class. During the treat-
ments, the data of the patients were registered according to the
RPA categories; therefore the graded prognostic assessment
(GPA) could not be defined retrospectively in lack of
Karnofsky index between 70 and 100. Nevertheless, the treat-
ment outcome could be evaluated according to the number of
brain metastases.
Table 1 summarises the patient characteristics according
to the three different methods of treatment. Patient distribution
according to the age, gender and primary tumour localisation,
extracranial metastasis were similar in the 3 groups. The dif-
ference of the KPS at the diagnosis and consequently the
patient distribution according to the RPA categories shows
the patient selection strategy at our Department. In RPA 2,
the primary tumour was controlled in 13%, uncontrolled in
63%, unknown in 24% of the cases. In RPA 3, this distribution
was 10%, 78%, and 12%, respectively.
Characteristics of the Malignant Disease and Brain
Metastases
Extracranial metastasis was present 53% in the RPA 2, and
56% of the cases in the RPA 3 group. Extracranial metastasis
was not present in 30% and 38%, or was unknown in 17% and
6% of the cases in RPA 2 and 3 classes, respectively. Higher
number of the patients received high dose radiotherapy with
good PS, with better prognostic factors and with solitary or
oligometastases. The difference according to the KPS and
RPAwas less pronounced in the Group C, then in the Group
B over the Group A. Even the status of extracranial disease
was less favourable in the Group C with 50% progressive
disease, in contrast to 36% in the Group A and 21% in the
Group B. Table 2 characterises the brain metastases further.
The time frame of brain metastasis occurrence had a relation
to the underlying disease, hence were similarly distributed
between the treatment groups. The development of brain me-
tastases occurred within 1 year after the diagnosis of primary
tumour in 72% of the patients in Group A, 66% in Group B
and 64% in Group C. Late occurring brain metastases were
diagnosed in 13.8%, 14.4% and 17.6% in the Groups A, B, C,
respectively. The rate of single−/oligometastases was higher
than two third of the group when the higher total dose was
applied (Groups B and C), and was 42% of the patients re-
ceivedWBRTonly. Consequently, only 10% of the patients of
Group A underwent surgery, meanwhile almost the half of the
patients was subjected to neurosurgical removal of the metas-
tases in the other two groups. 147 patients were subjected to
brain metastasectomy, 90% of them also received postopera-
tive/ adjuvant radiotherapy, independently from the ra-
diotherapy modality. The planning target volume (PTV)
for the WBRT was similar in the three groups. The dif-
ference between the boost PTVs of the Groups B (153.3
± 27.9 cm3) and C (183.1 ± 15.7 cm3) was statistically
significant (p = 0.017).
Survival Analysis
The analysis of OS according to different factors is
summarised in Table 3. Doubling of the survival time was
detected in the escalated dose groups over the Group A.
(p < 0.001) The OS was 3.2–3.3 months for all tumour types,
if only WBRT was applied. OS difference was significant in
the case of lung cancer and malignant melanoma between
patients treated by WBRT only vs. those receiving escalated
total dose. OS difference has not reached the statistical signif-
icance level for breast, kidney and gastrointestinal tumours.
Both in the case of low number of the BM (1–3) and in the
case of multiple (>4) metastases, the OS difference between
the 30Gy and escalated groups were significant. If surgery
was performed, statistically no OS benefit could be proven
from the boost dose (p = 0.48), in contrast to the significantly
prolonged survival without neurosurgical removal (p =
0.002). The longer treatment with higher total dose (SIB or
consecutive boost to WBRT) was significantly more benefi-
cial for the survival of patients both in good and in poor con-
dition (Table 4). The survival data of the Group B and C in
RPA classes 2 and 3 were significantly better than in Group A.
Only a few patients in RPA class 1 were treated with WBRT,
therefore in spite of the median survival of Group B
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(20.2 months) and in Group C (14.6 months) in contrast to the
6.3 months of Group A; it has not reached the statistical sig-
nificance (Table 4). Kaplan-Meier survival analysis detected
no significant OS difference between the treatment groups for
the patients of RPA 1 category. As for the RPA 2 and RPA3
categories, the OS was significantly prolonged in case of pa-
tients received escalated dose, 4.0 vs. 7.7 months; (p = 0.002)
in class RPA2 and 2.6 vs. 4.2 months; (p < 0.0001) in the class
RPA 3. If no surgery was performed the SIB resulted in sig-
nificantly longer OS of 6.5 months in contrast to the
3.9 months survival of the patients received WBRT only for
class 1–2 (p = 0.05). In RPA class 3, the addition of both the
consecutive or delayed boost and the simultaneous boost to
the WBRT resulted in significant OS benefit (p = 0.001). The
OS of patients with KPS > 70% and even the OS of patients
with KPS < 70% were equally proven better in case of those
receiving the escalated dose vs. WBRTwithout boost (9.4 vs.
4.2 months; p < 0.0001 and 4.2 vs. 2.6 months; p < 0.0001;
respectively). The multi-variance analysis yielded three, mu-
tually independent prognostic factors for survival: RPA, sur-
gery and therapy method. According to this analysis, the num-
ber of metastases, as a prognostic factor, is not independent
from the ones mentioned above (as shown in Table 5).
Toxicity of the Treatment
In the majority of the cases in each group, the prophylactic
dose of the methyl-prednisolone prevented the development
Table 1 Patient characteristics by treatment groups
Treatment group AWBRT
10 × 3Gy
n = 195
B WBRT+ boost
10 × 3/18 × 2 + 10 × 2
n = 125
C SIB
15×(2.2 + 0.7)
n = 148
B + C group
n = 273
Age
Mean 60.9 58.3 63.1 60.7
Range 27.6–84.2 21.6–84.7 38.3–84.8 21.6–84.8
< 50 20 (10.3%) 28 (22.4%) 10 (6.8%) 38(13%)
50–70 135 (69.2%) 78 (62.4%) 103 (69.6%) 181 (66%)
> 70 40 (20.5%) 19 (15.2%) 35 (23.6%) 54 (19%)
Gender
Male 107 (54.9%) 69 (55.2%) 74 (50%) 143(52%)
Female 88 (45.1%) 56 (44.8%) 74 (50%) 130(48%)
Primary tumour
Lung (total) 143 (73.3%) 85 (68%) 97 (65.6%) 182(66%)
-SCLC 35 (17.9%) 7 (5.6%) 13 (8.7%) 20 (7.3%)
-NSCLC 108 (55.3%) 78 (62.4%) 84 (56.7%) 162 (59.3%)
Breast 16 (8.2%) 7 (5.6%) 15 (10.1%) 22(8%)
MM 9 (4.6%) 18 (14.4%) 19 (12.8%) 37(13%)
Kidney 5 (2.6%) 3 (2.4%) 2 (1.4%) 5(1.8%)
Colorectal 10 (5.1%) 8 (6.4%) 7 (4.7%) 15(5.4%)
Other 12 (6.2%) 4 (3.2%) 8 (5.4%) 12(4.3%)
KPS
> 70 81 (41.5%) 93 (74.4%) 78 (52.7%) 171(62%)
< 70 114 (58.5%) 32 (25.6%) 70 (47.3%) 102(37%)
Status of extracranial dissemination
No. 67 (34.4%) 63 (50.4%) 19 (12.8%) 82(30%)
Regression 10 (5.1%) 8 (6.4%) 5 (3.4%) 13 (4.7%)
Progression 70 (35.9%) 27 (21.6%) 74 (50%) 101(37%)
Unknown 48 (24.6%) 27 (21.6%) 50 (33.8%) 77(28%)
RPA
1 8 (4.1%) 28 (22.4%) 10 (6.8%) 38 (14%)
2 73 (37.4%) 65 (52%) 68 (45.9%) 133 (48%)
3 114 (58.5%) 32 (25.6%) 70 (47.3%) 102(38%)
MM=malignant melanoma
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of serious brain oedema, the consequent intracranial pressure
elevation, and the aggravation of the neurological symptoms.
In 35% of the cases, the dehydration had to be intensified, but
with appropriate supportive control, 96% of the patients could
complete the planned therapy. Alopecia occurred in all groups
equally.
Discussion
There is still a seething debate concerning the optimal man-
agement of brain metastases. The main aim that everyone
agrees with is to achieve as long time for the patients as pos-
sible without physical and psychological signs and symptoms.
Table 3 The OS directly related to the type of irradiation, primary tumour, number of brain metastases and metastasectomy
The investigated parameters Type of irradiation n OS ±SE p-value
Type of irradiation WBRT (group A) 195 3.3 0.29 <0.0001 *
Escalated dose (groups B + C) 273 6.5 0.539
Primary tumor Lung cancer WBRT (group A) 144 3.3 0.314 <0.0001 *
Escalated dose (groups B + C) 184 7.1 0.698
Breast cancer WBRT (group A) 15 3.3 0.506 0.51
Escalated dose (groups B + C) 22 5.5 0.916
Melanoma WBRT (group A) 9 3.2 0.894 0.03*
Escalated dose (groups B + C) 37 6.5 1.366
Gastrointestinal WBRT (group A) 10 3.2 0.712 0.13
Escalated dose (groups B + C) 13 5.6 0.539
Number of brain metastases Solitary brain metastases WBRT (group A) 32 4.7 1.075 0.1
Escalated dose (groups B + C) 143 7.1 0.911
Oligo metastases WBRT (group A) 34 2.6 0.292 0.002*
Escalated dose (groups B + C) 72 5.4 1.196
>4 metastases (multiplex) WBRT (group A) 124 2.9 0.295 0.001*
Escalated dose (groups B + C) 58 5.7 0.645
Brain surgery Metastasectomy WBRT (group A) 19 8.4 2.298 0.48
Escalated dose (groups B + C) 127 9.9 0.946
NO metastasectomy WBRT (group A) 176 2.9 0.252 0.002*
Escalated dose (groups B + C) 145 4.4 0.415
Table 2 Characteristics of brain metastases by treatment groups
Treatment group AWBRT
10x3Gy
B WBRT+ boost
10 × 3/18 × 2 + 10X2
C SIB
15×(2.2 + 0.7)
Development of BM after the diagnosis of the primary
First manifestation of the disease or within 1 year 140 (71.8%) 83 (66.4%) 95 (64.2%)
1–3 years 28 (14.4%) 24 (19.2%) 27 (18.2%)
> 4 years 27 (13.8%) 18 (14.4%) 26 (17.6%)
Number of BM
average 5,1 2,2 2,9
1 38 (19.5%) 78 (62.4%) 69 (46.6%)
2–4 44 (22.6%) 29 (23.2%) 50 (33.8%)
> 4 113 (57.9%) 18 (14.4%) 29 (19.6)
BM surgery
no 176 (90.3%) 63 (50.4%) 82 (55.4%)
yes 19 (9.7%) 62 (49.6%) 66 (44.6%)
RT volumes of interest
PTV 1705 1716 1686
PTV1 153.3 183.1
Brain 1326 1341 1314
GTV 35.9 59.1
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Historically, the very short survival without treatment, with
the symptoms of increasing intracranial pressure and diverse
neurological deteriorations including motor-, sensory-,
speech- and cognitive dysfunctions led to delivery of pallia-
tive 30 Gy WBRT, in 10 fractions [20]. Ten or five consecu-
tive working days were reasonable even for patients in poor
condition with short life expectancy and the RT was per-
formed with simple technique (two opposed lateral beams)
with relative large dose inhomogeneity in the whole brain.
Nevertheless, WBRT resulted in symptom relief in the major-
ity of the patients, and added some months to their survival
[21]. Based on that, WBRT became the standard management
of brain metastasis [22] and had been also introduced as pre-
ventive measure in case of radiosensitive malignancy with
high risk for BM or leptomeningeal dissemination (ALL,
SCLC) [23, 24]. The prophylactic WBRT is performed with
conventional fractionation (1.8–2 Gy/fraction). There is no
doubt that WBRT is highly effective to prevent metastatic
spread in the brain, but severe neurocognitive decline
(particularly memory deficit) occurs with high probability af-
ter 5x4Gy or 10x3Gy [25]. The introduction of stereotactic
radiosurgery technique in the 1960s provided access to highly
selective dose delivery method for small (<3 cm), and low
number (1–3) of brain metastases, which was applied as alter-
native method to neurosurgical intervention. Several clinical
studies proved the superiority of the combined treatment, sur-
gery or SRS +WBRT to improve local and central nervous
system control [10, 26–29]. In the last decade, with the advent
of imaging (CAT/MRI), development of neurosurgery tech-
nique and various SRS solutions, high precision local man-
agement of single and oligo-BM became widely available.
Recent clinical trials and meta-analyses questioned the neces-
sity of WBRT at all, emphasising the neurocognitive harm of
the WBRT [12, 30–34]. Meanwhile, other authors [35] warn
of drawing too early and hasty conclusions leading to general
omission of WBRT, without considering the danger of in-
crease of intracranial impairments, and neurocognitive decline
due to cerebral disease progression. They rather suggest con-
sidering the use of selective neuroprotective agent
(memantine) and hippocampus-sparing WBRT technique
[36, 37]. Chung et al. [15]. applied a lower WBRT dose with
a boost to the tumour bed after metastasectomy, since WBRT
neurotoxicity is associated with the total dose and fraction-
ation [38]. Although no randomized studies have directly
compared lower WBRT doses to the traditional WBRT dose
of 30 Gy, the advantage of lowerWBRT dose has been shown
in previous studies on prophylactic cranial irradiation (PCI).
For example, a French study compared PCI (24 Gy in 8 frac-
tions, EQD2 26 Gy) vs. no PCI, and observed no significant
Table 4 The OS as a function of
Karnovsky-scores or RPA The investigated parameters Type of irradiation n OS ±SE p-value
Karnofsky > 70% WBRTSIB 81
78
4.1
8.9
0.45
0.867
0.015
WBRTWBRT+boost 81
93
4.1
9.6
0.45
0.868
<0.0001
Karnofsky < 70% WBRTSIB 114
70
2.6
3.9
0.19
0.465
0.002
WBRTWBRT+boost 114
32
2.6
4.2
0.19
0.636
0.021
RPA1 WBRTSIB 8
10
6.3
20.2
6.223
2.972
0.343
WBRTWBRT+boost 8
28
6.3
14.6
6.223
6.456
0.345
RPA2 WBRTSIB 73
68
4.0
7.7
0.427
1.052
0.034
WBRTWBRT+boost 73
65
4.0
8.3
0.427
1.875
0.003
RPA3 WBRTSIB 114
70
2.6
3.9
0.19
0.465
0.002
WBRTWBRT+boost 114
32
2.6
4.2
0.19
0.636
0.021
Table 5 RPA, surgery and RT method, as prognostic factors for
survival
Risk factors HR 95% CI p-value
RPA <0.001
RPA 3 vs. RPA 1 3.546 2.463–5.102
RPA 3 vs. RPA 2 1.773 1.441–2.183
Surgery NO vs. YES 2.072 1.643–2.512 <0.001
RT group Group A vs. Group B,C 1.256 1.021–1.546 0.031
Á. Dobi et al.
difference between the groups in terms of neuropsychological
function or abnormalities [39]. In another trial performed at
MD Anderson Cancer Centre, 30 patients received PCI
(25 Gy in 10 fractions, EQD2 26.04 Gy) and no significant
deterioration was observed after PCI [40]. Other approach to
reduce the decrease of memory function could be the use of
lower fraction doses.
Our aim was to find a balance in improving the survival
with dose escalation to the macroscopic metastases, maintain-
ing the intracranial control and reducing the probability of
treatment-related cognitive decline; meanwhile keeping the
treatment duration reasonable for patients even with multiple
brain metastases. Therefore, we have applied conventional
fractionation for 3D conformal whole brain and consecutive
boost irradiation using the classical conventional fractionation
scheme, 18x2Gy + 10 to 12x2Gy up to 56–60 Gy total dose
for patients with relatively longer life expectancy. Later we
have introduced a shortened regime of 15 × 2.2 Gy whole
brain irradiation and simultaneously 0.7 Gy was delivered to
the tumour or tumour bed after surgery. This technique
allowed encompassing even 10–12 metastases into the boost
volume, and lasted only 3 weeks, considered reasonable for
patients with poorer condition. Tiwari and co-workers report-
ed the results of SIB of 19 patients versus WBRT alone (13
patients), demonstrating better local control and improved sur-
vival in the SIB group [41]. Another publication from Italian
groups emphasises the higher efficacy of the intensified treat-
ment (WBRT and SRS boost), as well, enrolling 134 patients,
of whom 21 were treated with SIB [28]. On the basis of high
patient number, we could demonstrate the feasibility and clin-
ical usefulness of dose escalation and in particular, the appli-
cation of SIB in the management of BM, even for patients
with unfavourable status. Direct comparison of SRS to SIB
was performed in a matched cohort of 178 patients with sim-
ilar baseline characteristics [42]. However, as for the OS, nei-
ther the treatment with SRS nor with SIB did result in any
statistically significant difference, the SIB was associated with
reduced intracranial impairment, likely due to the WBRT
component of the treatment (HR 0.36, p < 0.001). Similarly
for single and oligometastatic brain spread, several
randomised clinical studies have proven the better outcome
in terms of local and intracranial disease control with com-
bined treatment approaches, such as surgery +WBRT, SRS +
WBRT, or SIB; but in the majority of the cases these encour-
aging results could not be transformed into significantly im-
proved survival [13, 15, 28, 42–44].
In contrast, our retrospective analysis confirmed the signif-
icant survival benefit for the whole group of patients including
multiple metastases from intensified treatments without differ-
ence between the long and the shortened (SIB) regimes. This
relevant survival difference was achieved not only for
oligometastatic diseases, but for patients with multiple metas-
tases (>4), as well. Hence, in the group that received SIB, one
fifth of the patients had multiple metastases, in which the
simultaneous boost was technically performable. The majority
of evidence-based data derived from randomised clinical stud-
ies concerns patient population with single or oligometastases
only, without progressing extracranial disease and in good
status. Nevertheless, patients with worse initial parameters
could not be enrolled – by forming homogeneous groups- into
randomised trials. In fact, the design of clinical investigation
on the management of brain metastasis is a highly challenging
task. The application of the suggested recommendations of the
Response Assessment in Neuro-Oncology (RANO) brain me-
tastases group [45, 46] supposes patients in good condition
and good cooperation, what is frequently not the case with
patients of progressing extracranial cancer and/or low perfor-
mance status. In our current study population, around half of
the patients in the SIB arm had progressive disease and bad
performance status (<70%), according to Karnofsky score.
Our study has evident limitations. Its retrospective nature
and consequent patient heterogeneity may have biased the
results. Our effort to compare the outcome of the different
treatment schemes by retrospectively dividing the patient pop-
ulation amongst similar prognostic groups could not
completely compensate the lack of prospective patient enrol-
ment. Furthermore, no objective assessment of late neurotox-
icity has been performed. However, this study has several
strengths. The large number of the patients allowed relevant
statistical evaluation, and the three treatment approaches were
clearly defined. Our aim to study the feasibility of SIB in 15
fractions even for patients, who cannot be enrolled into pro-
spective clinical trials due to their bad prognostics, could be
investigated. Conclusion could be drawn from this analysis on
the applicability of lower WBRT fraction dose approach with
a boost RT.
Therefore, considering all the limitations, our study on
large patient series in RPA2 and RPA3 categories seems to
document survival advantage of intensified irradiation
schemes, which has high importance for the daily clinical
decisions, even for patients in poor condition (KPS < 70%).
The novel generation of linear accelerators allow the introduc-
tion of fractionated stereotactic irradiation of the boost vol-
umes simultaneously to the low fraction size (< 2.5 Gy)
WBRT.
Conclusion
The improvement in the systemic treatment of disseminated
malignancies urges the establishment of optimal management
of patients with brain metastasis with different clinical and
tumour parameters. Meanwhile, some open questions could
be hopefully answered soon by the results of the on-going
trials on radiation technique and on combination of radiother-
apy with targeted agents for patients with low number of BMs.
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Still, novel approaches are highly required to decrease the
potential neurocognitive decline as a consequence of WBRT,
since the majority of the patients belong to less favourable
prognostic groups (i.e. with progressive extracranial status
and multiple BMs). Therefore, retrospective analyses could
provide valuable conclusions, even though they should be
assessed critically. From our large series of evaluation, the
intensive radiation approach for groups of BM patients seems
to yield clinical benefit; and the feasibility of SIB in the man-
agement of BMs could be confirmed. Together with the use of
neuroprotective agents and hippocampal-avoidance WBRT
technique, smaller fraction size of WBRT simultaneously to
fSRT boost is to be considered for further clinical
investigation.
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